Introduction
Overview
Mermaid diagram (expand to render)
Induced pluripotent stem cell (iPSC) technology has revolutionized the study of neurodegenerative diseases, providing patient-derived cellular models that recapitulate disease-relevant phenotypes in ways that animal models cannot fully achieve. Since Shinya Yamanaka's Nobel Prize-winning discovery of cellular reprogramming in 2006, iPSC-derived neuronal and glial models have become indispensable tools for understanding disease mechanisms, identifying drug targets, and screening therapeutics for conditions including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis), [Huntington's disease](/mechanisms/huntington-pathway), and [frontotemporal dementia](/diseases/frontotemporal-dementia) ([Okano et al., 2026](https://pubmed.ncbi.nlm.nih.gov/41213329/)). [@takahashi2006]
iPSC disease modeling offers several critical advantages over traditional approaches: it preserves the patient's complete genetic background, enables the study of human-specific disease mechanisms, provides access to cell types that are otherwise inaccessible (such as cortical pyramidal neurons and dopaminergic neurons), and reduces reliance on animal models. The integration of iPSC technology with [CRISPR gene editing](/therapeutics/crispr-gene-editing), [brain organoids](/technologies/brain-organoids), and high-throughput screening has further expanded the utility of these models for precision medicine and drug discovery ([Li et al., 2024](https://doi.org/10.3389/fnins.2024.1434945)).
Reprogramming and Differentiation
Generation of iPSCs
iPSCs are generated by introducing a defined set of transcription factors—typically OCT4, SOX2, KLF4, and c-MYC (the Yamanaka factors)—into somatic cells such as skin fibroblasts or peripheral blood mononuclear cells (PBMCs). Modern reprogramming protocols have moved beyond retroviral integration to use non-integrating methods including Sendai virus, episomal plasmids, modified mRNA, and small-molecule cocktails, reducing the risk of insertional mutagenesis and improving the safety profile of derived cells ([Takahashi et al., 2006](https://doi.org/10.1016/j.cell.2006.07.024)).
Quality control of iPSCs involves verification of pluripotency marker expression (NANOG, TRA-1-60, SSEA-4), karyotype stability, and confirmation of differentiation potential through trilineage differentiation assays. The International Stem Cell Initiative and the Induced Pluripotent Stem Cell Initiative (iPSCi) have established standardized protocols for iPSC generation and characterization ([Marchetto et al., 2011](https://doi.org/10.1093/hmg/ddr336)).
Neural Differentiation Protocols
iPSCs can be differentiated into virtually any neural cell type through carefully optimized protocols:
- Cortical [neurons](/entities/neurons): Dual SMAD inhibition (SB431542 + LDN193189) followed by WNT inhibition to generate cortical progenitors, which mature into glutamatergic [neurons](/entities/neurons) relevant to [Alzheimer's disease](/diseases/alzheimers-disease) and [frontotemporal dementia](/diseases/frontotemporal-dementia).
- Dopaminergic [neurons](/entities/neurons): Floor plate-based differentiation using SHH agonists and FGF8 to generate midbrain dopaminergic [neurons](/entities/neurons) expressing tyrosine hydroxylase, critical for modeling [Parkinson's disease](/diseases/parkinsons-disease).
- Motor [neurons](/entities/neurons): Caudalization with retinoic acid and ventralization with SHH agonists to produce spinal motor [neurons](/entities/neurons) for [ALS](/diseases/amyotrophic-lateral-sclerosis) and [spinal muscular atrophy](/diseases/spinal-muscular-atrophy) research.
- [Astrocytes)/cell-types/[astrocytes): Extended differentiation protocols generating [GFAP](/entities/glial-fibrillary-acidic-protein)-positive cells that exhibit calcium signaling, glutamate uptake, and inflammatory responses.
- [Oligodendrocytes](/cell-types/oligodendrocytes): Protocols generating myelinating oligodendrocytes for studying [demyelination](/mechanisms/demyelination) in [multiple sclerosis](/diseases/multiple-sclerosis) and leukodystrophies.
Disease-Specific Applications
Alzheimer's Disease
iPSC models have been instrumental in dissecting the complex pathobiology of [Alzheimer's disease](/diseases/alzheimers-disease). Patient-derived [neurons](/entities/neurons) carrying mutations in [APP](/entities/app-protein), [PSEN1)](/entities/psen1), and [PSEN2](/genes/psen2) recapitulate key disease features including increased [amyloid-beta](/proteins/amyloid-beta) production (particularly the [Aβ42](/proteins/amyloid-beta)/40 ratio), elevated tau] phosphorylation], endosomal enlargement, and altered calcium signaling ([Bhatt et al., 2025](https://doi.org/10.1038/s41380-025-03041-w)).
Key findings from iPSC-based Alzheimer's research include:
- APOE4 effects: iPSC-derived [neurons](/entities/neurons) and [astrocytes](/cell-types/astrocytes) from [APOE4 show increased [Aβ](/proteins/amyloid-beta-protein) production, impaired lipid metabolism, and enhanced inflammatory responses. Isogenic APOE3/APOE4 pairs generated by CRISPR editing have demonstrated that APOE4 impairs astrocyte-mediated [Aβ](/proteins/amyloid-beta-protein) clearance and increases neuronal vulnerability to tau] pathology (Zhao et al., 2020, Nature Communications.
- Amyloid processing: Patient neurons with familial AD mutations show elevated [BACE1](/proteins/bace1-protein) carrying mutations in [LRRK2](/proteins/lrrk2-protein), [SNCA)](/proteins/snca-protein), [PINK1](/proteins/pink1-protein), [PRKN](/genes/prkn), [GBA](/proteins/gba-protein), and [PARK7 (DJ-1)](/proteins/park7-protein) to reveal disease mechanisms:
- [alpha-synuclein](/proteins/alpha-synuclein): The G2019S mutation, the most common genetic cause of PD, leads to increased kinase activity, impaired neurite outgrowth, and enhanced α-synuclein accumulation in iPSC-derived dopaminergic neurons.
- [GBA1](/proteins/gba-protein): GBA-mutant iPSC neurons demonstrate [lysosomal dysfunction](/mechanisms/lysosomal-dysfunction), glucocerebrosidase deficiency, and α-synuclein accumulation, connecting [Gaucher disease](/diseases/gaucher-disease) biology to PD pathogenesis.
Amyotrophic Lateral Sclerosis
iPSC-derived [motor neurons](/cell-types/motor-neurons) from ALS patients carrying mutations in [SOD1](/proteins/sod1-protein), [C9orf72](/genes/c9orf72), [TARDBP](/genes/tardbp), and [FUS](/entities/fus) have revealed critical disease mechanisms ([Fujimori et al., 2018](https://doi.org/10.1038/s41591-018-0140-5)):
- [TDP-43](/proteins/tdp-43) proteinopathy]: iPSC motor neurons from [TARDBP](/genes/tardbp)-mutant patients show cytoplasmic [TDP-43](/proteins/tdp-43) mislocalization, stress granule formation, and nuclear depletion of [TDP-43](/proteins/tdp-43).
- [C9orf72](/genes/c9orf72) repeat expansion: Patient motor neurons exhibit RNA foci, [dipeptide repeat](/proteins/c9orf72-dprs), [nucleocytoplasmic transport defects](/mechanisms/nucleocytoplasmic-transport-defects), and impaired [autophagy](/mechanisms/autophagy-lysosome-neurodegeneration).
- SOD1 toxicity: iPSC-derived motor neurons expressing mutant [SOD1/proteins/sod1 display protein aggregation, excitotoxicity, and axonal transport dysfunction.
Huntington's Disease
iPSC models carrying expanded CAG repeats in the [HTT](/genes/htt) gene recapitulate features of [Huntington's disease](/mechanisms/huntington-pathway), including [huntingtin](/proteins/huntingtin) protein/proteins/[huntingtin](/proteins/huntingtin) aggregation, transcriptional dysregulation, impaired BDNF signaling, and [medium spiny neuron](/cell-types/medium-spiny-neurons) vulnerability. These models have been particularly valuable for testing [antisense oligonucleotide](/therapeutics/antisense-oligonucleotide-therapy) therapies targeting mutant [HTT](/genes/htt) mRNA.
Frontotemporal Dementia
iPSC models of [FTD](/diseases/frontotemporal-dementia) derived from patients with mutations in [MAPT](/genes/mapt), [GRN](/genes/grn), and [C9orf72](/genes/c9orf72) have provided insights into tau] pathology], [progranulin](/proteins/progranulin) haploinsufficiency, and the convergent downstream mechanisms shared across FTD subtypes including [lysosomal dysfunction](/mechanisms/lysosomal-dysfunction) and neuroinflammation.
Advanced Model Systems
Brain Organoids
Cerebral organoids—three-dimensional self-organized neural tissues derived from iPSCs—represent a major advance in modeling neurodegenerative diseases. These complex structures recapitulate aspects of human brain development and contain multiple neural cell types organized in layers reminiscent of cortical architecture. Recent advances include:
- Vascularized neuroimmune organoids: A 2025 study demonstrated that organoids containing neurons, [microglia](/cell-types/microglia)/cell-types/[microglia/cell-types/[astrocytes), and blood vessels, when exposed to AD brain extracts, developed [Aβ](/proteins/amyloid-beta-protein) plaque-like aggregates, tau] tangle-like aggregates, neuroinflammation, elevated microglial synaptic pruning, and neuronal loss within four weeks (Bhatt et al., 2025, Molecular Psychiatry).
- Region-specific organoids: Protocols now generate organoids representing specific brain regions including the midbrain (for PD research), [hippocampus](/brain-regions/hippocampus) (for AD), and spinal cord (for ALS).
- Assembloids: Fused organoids from different brain regions enable the study of inter-regional connectivity and disease propagation, including [prion-like spreading](/mechanisms/prion-like-spreading) of pathological proteins.
CRISPR-Engineered Isogenic Lines
[CRISPR gene editing](/therapeutics/crispr-gene-editing) has transformed iPSC disease modeling by enabling the creation of isogenic cell line pairs that differ only at a single genetic locus. This approach eliminates confounding genetic background effects and allows precise attribution of phenotypic changes to specific mutations. Applications include:
- Correction of disease-causing mutations in patient-derived iPSCs to create "repaired" controls
- Introduction of risk variants ([APOE4](/diseases/apoe4), [TREM2](/proteins/trem2-protein) R47H) into control lines to study variant-specific effects
- Creation of reporter lines for real-time visualization of protein aggregation and cellular stress
- Multiplexed editing to study gene-gene interactions in complex disease
Co-Culture and Multi-Cell Type Systems
Neurodegenerative diseases involve complex interactions between neurons, glia, and immune cells. Advanced iPSC co-culture systems include:
- Neuron-[microglia](/cell-types/microglia)
- Neuronal survival and neurite outgrowth
- Mitochondrial function and calcium homeostasis
Several compounds identified through iPSC-based screens have progressed to clinical trials. Notable examples include ropinirole for ALS (identified through iPSC motor neuron screening) and multiple LRRK2 kinase inhibitors validated in iPSC-derived dopaminergic neurons.
Personalized Medicine
iPSC models enable patient-specific drug testing, identifying responders and non-responders before clinical treatment. This pharmacogenomic approach is particularly relevant for diseases with heterogeneous genetic bases, allowing stratification of patients for clinical trials and prediction of individual drug responses.
Toxicity Assessment
iPSC-derived neurons and cardiomyocytes enable early detection of neurotoxicity and cardiotoxicity in drug development pipelines, reducing late-stage clinical trial failures.
Limitations and Challenges
Despite their transformative potential, iPSC disease models face several important limitations:
- Maturation and aging: iPSC-derived neurons typically exhibit fetal-like gene expression profiles. Modeling age-related neurodegenerative diseases requires artificial aging strategies including progerin overexpression, telomere shortening, or extended culture periods.
- Variability: Line-to-line and differentiation-batch variability can confound results, requiring large sample sizes and rigorous quality control.
- Complexity: Even advanced organoid models lack the full complexity of the human brain, including vascularization, immune surveillance, and circuit-level connectivity.
- Scalability: The cost and time required for iPSC generation, differentiation, and maturation limit throughput compared to immortalized cell lines.
- Epigenetic resetting: Reprogramming to pluripotency erases age-related epigenetic marks, including [DNA methylation](/entities/dna-methylation) and [histone modifications](/entities/histone-modifications), which may be relevant to disease pathogenesis.
Key Resources and Biobanks
Several major biobanks maintain collections of well-characterized iPSC lines for neurodegenerative disease research:
- iPS Cells for Neurodegenerative Disease (iNDI): An NIH-funded initiative generating iPSC lines from patients with diverse neurodegenerative diseases.
- New York Stem Cell Foundation (NYSCF): Automated iPSC derivation and distribution.
- European Bank for induced Pluripotent Stem Cells (EBiSC): Centralized repository with standardized quality control.
- WiCell Research Institute: Distribution of iPSC lines for academic research.
- Coriell Institute: Maintains iPSC lines from the NINDS Repository.
Future Directions
The field of iPSC disease modeling is evolving rapidly, with several emerging directions:
- Organ-on-chip integration: Combining iPSC-derived cells with microfluidic platforms to model the [Blood-Brain Barrier](/entities/blood-brain-barrier), neurovascular unit, and systemic interactions.
- Multi-omics profiling: Single-cell RNA sequencing, proteomics, and metabolomics of iPSC-derived cells to identify novel disease signatures and drug targets.
- Artificial intelligence integration: Machine learning analysis of high-content imaging data from iPSC screens to identify subtle phenotypic changes and predict drug responses.
- Clinical-grade manufacturing: Advancing iPSC-derived cell therapies from bench to bedside, including dopaminergic neuron transplantation for Parkinson's Disease.
- Patient avatars: Creating comprehensive iPSC-based models that capture individual patient biology for personalized treatment selection.
See Also
- [microglia](/cell-types/microglia)/entities/microglia:663-676. [DOI](https://doi.org/10.1016/j.cell.2006.07.024)
2. [Penney J, Ralvenius WT, Tsai LH. Modeling Alzheimer's Disease with iPSC-derived brain cells.
Molecular Psychiatry. 2020;25(1):148-167. [DOI](https://doi.org/10.1038/s41380-019-0468-3)
[Bhatt N, et al. Alzheimer's Disease patient brain extracts induce multiple pathologies in novel vascularized neuroimmune organoids. Molecular Psychiatry. 2025. [DOI](https://doi.org/10.1038/s41380-025-03041-w)
[Zhao J, et al. APOE4 exacerbates synapse loss and neurodegeneration in Alzheimer's Disease patient iPSC-derived cerebral organoids. Nature Communications. 2020;11(1):5540. [DOI](https://doi.org/10.1038/s41467-020-19264-0)
[Chang CY, et al. Current development of iPSC-based modeling in neurodegenerative diseases. International Journal of Molecular Sciences. 2025;26(8):3774. [DOI](https://doi.org/10.3390/ijms26083774)
[Okano H, Morimoto S. Drug discovery research with iPSC models of neurodegenerative diseases. Neuroscience Research. 2026. [doi:10.1016/j.neures.2025.07.003](https://pubmed.ncbi.nlm.nih.gov/41213329/)
[Marchetto MC, et al. Induced pluripotent stem cells (iPSCs) and neurological disease modeling: progress and promises. Human Molecular Genetics. 2011;20(R2):R109-R115. [DOI](https://doi.org/10.1093/hmg/ddr336)
[Soldner F, Jaenisch R. Stem cells, genome editing, and the path to translational medicine. Cell. 2018;175(3):615-632. [DOI](https://doi.org/10.1016/j.cell.2018.09.010)
[Ramos DM, et al. Tackling neurodegenerative diseases with genomic engineering: a new stem cell initiative from the NIH. Neuron. 2021;109(7):1080-1083. [DOI](https://doi.org/10.1016/j.neuron.2021.03.022)
[Fujimori K, et al. Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. Nature Medicine. 2018;24(10):1579-1589. [DOI](https://doi.org/10.1038/s41591-018-0140-5)
[Mertens J, et al. Directly reprogrammed human neurons retain aging-associated transcriptomic signatures and reveal age-related nucleocytoplasmic defects. Cell Stem Cell. 2015;17(6):705-718. [DOI](https://doi.org/10.1016/j.stem.2015.09.001)
[Li Y, et al. Modeling Alzheimer's Disease using human cell derived brain organoids and 3D models. Frontiers in Neuroscience. 2024;18:1434945. [DOI](https://doi.org/10.3389/fnins.2024.1434945)External Links
- [iPSC Research - NIH](https://www.nih.gov/stem-cell-basics)
- [Stem Cell Information - NIH](https://stemcells.nih.gov)
- [iPSC Disease Models - Nature Methods](https://www.nature.com/articles/s41592-019-0648-6)
Background
The study of Induced Pluripotent Stem Cell (Ipsc) Disease Models has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[Unknown, Takahashi & Yamanaka, Induction of pluripotent stem cells (2006) (2006)](https://doi.org/10.1016/j.cell.2006.07.024)
[Bellin et al., Induced pluripotent stem cells (2012) (2012)](https://doi.org/10.1016/j.stem.2012.08.015)
[Liu et al., iPSC-derived neurons for neurodegenerative disease modeling (2013) (2013)](https://doi.org/10.1016/j.tins.2013.01.008)
[Kondo et al., Modeling Alzheimer's disease with iPSCs (2013) (2013)](https://doi.org/10.1016/j.stem.2013.01.006)
[Unknown, Saha & Jaenisch, Technical challenges in using human iPSCs (2009) (2009)](https://doi.org/10.1016/j.stem.2009.09.014)
[Brennand et al., Modeling schizophrenia using human iPSC neurons (2015) (2015)](https://doi.org/10.1038/nature14236)
[Nguyen et al., Direct conversion of fibroblasts into functional neurons (2011) (2011)](https://doi.org/10.1038/nature10135)
[Chambers et al., Highly efficient neural conversion of human ESCs (2009) (2009)](https://doi.org/10.1016/j.stem.2009.05.012)
[Zhang et al., A systematic review of iPSC in neurodegeneration (2020) (2020)](https://doi.org/10.3389/fnins.2020.00466)
[Avior et al., Stem cell therapy in neurodegenerative diseases (2016) (2016)](https://doi.org/10.1038/nrneurol.2015.226)